Wednesday I shared a few specifics from Celgene Corporation’s 2010 annual report. You can read the company’s entire press release by going to Myeloma News.com and clicking on:
CELGENE REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2010 OPERATING AND FINANCIAL RESULTS.
Note how much progress the company is making finding cross-over markets for Revlimid and the yet to be FDA approved pomalidomide.
Interesting stuff. But I found several of Celgene’s 2011 goals for blood cancer to be far more relevant for my fellow patients. Let’s examine the list. The two goals which affect multiple myeloma patients are highlighted:
Submit REVLIMID® Newly Diagnosed Multiple Myeloma Regulatory Filing with FDA
Submit REVLIMID del 5q Myelodysplastic Syndromes Regulatory Filing With EMA
Launch ISTODAX® in Peripheral T-Cell Lymphoma in the United States
Complete Enrollment of Pomalidomide Phase III Trial in Myelofibrosis
Initiate Phase III Trial of Pomalidomide in Relapsed/Refractory Multiple Myeloma
Initiate Phase III Study of REVLIMID in Patients with Follicular Lymphoma
Complete Enrollment of Pivotal Phase II Trials Evaluating REVLIMID in Mantle Cell Lymphoma
Exciting, but SLOW! Revlimid is already being used “off label” in newly diagnosed patients nation-wide. But official FDA approval will help a few remaining patients who’s insurance companies are still being a “pain in the butt” and won’t pay for Revlimid as an initial therapy… And why is pomalidomide only now moving into State 3 trials? Frustrating!
Still, progress is being made.
Feel good and keep smiling! Pat